Moderna, Inc. (MRNA): analysis and signal as of September 4, 2026

Published on September 5, 2026 at 14:07 · Updated on September 5, 2026 at 14:07 · by Aurélien Ambert, QDNA

Exchange : NASDAQ · Sector : Healthcare

In short

The signal is weak, with a vote of 3/3. The main reason is the unfavorable balance between three potential catalysts and the binary risk of a trial failure on a stock already in technical extension of 174,6 % above its 200-session moving average.

Current signal: weak (vote 3/3)
Deterministic score: -2.0 → signal expected by the scale : no signal (September 10, 2026)
Layers: fundamentals : neutral, price : neutral, risks : –

Triggered rules

Rule	Weight
penalizes excessive volatility (ruin risk), survival comes first, irreversible loss outweighs the optimization of return	-1.5
penalizes direct holding of US securities in a CTO (US estate tax at death), favors a UCITS ETF domiciled in IE	-1.0
moderately favors a positive 12-1 month momentum (tailwind), BUT guardrail: costly rotation, long-term reversal, momentum crashes, a conviction signal, not a rotation trigger	+0.5

Thesis

KEYNOTE-942 in melanoma, mRNA-1010 for influenza, and the oncology program constitute three potential catalysts. These elements do not offset the binary risk of a trial failure. The stock exhibits a technical extension of 174,6 % above its 200-session moving average. The 2026 fundamentals are not verified, notably revenue, free cash flow, and forecasts. The context leaves an imbalance between the upside potential and the downside risk.

Bull case

The oncology pipeline, with mRNA-4157 developed with Merck and the KEYNOTE-942 trial, offers upside potential if the data are positive. The healthcare sector also benefits from a current macroeconomic weighting deemed favorable. A visible clinical success would constitute important support for the stock.

Bear case

The post-Covid trajectory remains structurally declining. The negative net result is not confirmed as turning positive for 2026. The stock’s sensitivity is high and does not correspond to a defensive reading of the healthcare sector. The technical extension reaches 174,6 % above the 200-session moving average. None of the events in the announced calendar, BCE, CLARITY, Arc or TSM, directly concerns Moderna.

Scenarios

The bullish scenario has a probability of 25 % and describes a gain of 40 % after a positive FDA authorization. The central scenario has a probability of 50 % and describes a change between minus 15 % and plus 10 % over six months. The bearish scenario has a probability of 25 % and describes a decline of 50 % in the event of a trial failure or a pipeline disappointment.

Risks

The main risk is a trial failure on a stock already technically extended. The thesis lacks fundamental confirmation: verified second-quarter 2026 revenue, positive 2026 free cash flow, or explicit annual 2026 forecasts. In the absence of these elements, the horizon remains uncertain and the bearish scenario may dominate.

Market positioning (short sellers)

Short interest / shares outstanding: 10.52 %
Days to cover: 1.00
Settlement date: 2026-08-31
Source: FINRA (disseminated on 2026-09-12)

Market information published by FINRA (consolidated short interest, all venues), no directional comment.

Signal history (last 12 months)

Date	Signal	New fact
September 4, 2026	weak (3/3)	No change.

Frequently asked questions

Why is the signal weak even though the vote is 3/3?

The 3/3 vote expresses agreement among the three assessments on the diagnosis. This agreement does not change the reading of the risk: the KEYNOTE-942 and mRNA-1010 catalysts have not yet produced published data. The technical extension of 174,6 % above the 200-session moving average makes the stock vulnerable to unfavorable news. The 2026 fundamentals remain unverified, which keeps the signal weak.

What bullish elements are noted in the analysis?

The analysis cites KEYNOTE-942 in melanoma, mRNA-1010 against influenza, and the oncology program, including the collaboration with Merck on mRNA-4157. These trials can bring upside if their results are positive. The healthcare sector also benefits from a macroeconomic weighting currently deemed favorable. These elements constitute a counterweight, but remain conditional on as-yet-unknown data.

What bearish elements are noted in the analysis?

The post-Covid trajectory is described as structurally declining. The negative net result is not confirmed as turning positive for 2026. The stock shows a technical extension of 174,6 % above its 200-session moving average. None of the calendar events, BCE, CLARITY, Arc or TSM, concerns Moderna in the short term. A trial failure or a pipeline disappointment would open the way to the bearish scenario.

How does the analysis distribute the scenario probabilities?

The bullish scenario receives a probability of 25 %, with a gain of 40 % after a positive FDA authorization. The central scenario receives a probability of 50 %, for a change between minus 15 % and plus 10 % over six months. The bearish scenario receives a probability of 25 %, with a decline of 50 % in the event of a trial failure or a pipeline disappointment.

Sources

The official filings below are the issuer's own, matched to this stock by its identifier (LEI, CIK or ISIN). The figures quoted above come from an automated arbitration: they have not been re-checked one by one.

July 31, 2026 — 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits (SEC · 8-K)
July 31, 2026 — 10-Q (SEC · 10-Q)
July 8, 2026 — 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; 7.01 Reg… (SEC · 8-K)
May 11, 2026 — 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statemen… (SEC · 8-K)

Automated AI analysis: limitations and transparency

This content is an automated analysis produced using artificial intelligence. Personal analysis for information purposes — no personalised investment advice. MMR content consists of general research. It does not take account of your financial circumstances, objectives or risk tolerance. Data, analyses and results, including those produced using artificial intelligence, may contain errors, be incomplete or become outdated. No return or outcome is guaranteed. All investments carry a risk of partial or total loss of capital. Past performance and simulations do not predict future results. Before making any decision, check information against original sources and, where necessary, consult an authorised professional. You remain responsible for your investment decisions. This notice does not exclude or limit any liability that cannot legally be excluded or limited.
Tool and analysis: QDNA, Aurélien Ambert.
Analysis (arbitration) completed on September 4, 2026; this page was completed on September 5, 2026 at 14:07 (UTC).
Interests: no position in the stock analysed (MRNA) is recorded in the data consulted on September 12, 2026 (UTC). This does not confirm the absence of holdings or other interests. The situation at the analysis publication date has not been reconstructed.
This declaration covers only recorded positions in this stock; it is not an exhaustive verification of other interests or remuneration.
Methodology: analysis chain, score formula and scale described on the public methodology page.
Analysis horizon: 2035.